Chronic Refractory Cough Treatment Market Size in the 7MM was ~USD 8,800 million in 2023, is expected to increase a significant CAGR by 2034, estimates DelveInsight | Merck & Co, GSK, NeRRe Therapeutics, Trevi Therapeutics, Beijing Tide Pharmaceutical, Be

DelveInsight's "Chronic Refractory Cough Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory Cough market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Discover Key Insights into the Chronic Refractory Cough Market with DelveInsight's In-Depth Report @ Chronic Refractory Cough Market Size- https://www.delveinsight.com/sample-request/chronic-refractory-cough-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chronic Refractory Cough Market Report
• In February 2025:- Nocion Therapeutics:- This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
• The United States holds the largest market share for Chronic Refractory Cough (CRC) compared to the EU4 (Germany, Italy, France, and Spain), the United Kingdom, and Japan, with an estimated market size of approximately USD 4,500 million in 2023.
• In 2023, Japan's market size for Chronic Refractory Cough (CRC) was approximately USD 1,100 million. The market is anticipated to grow further, primarily driven by the introduction of new therapies during the forecast period (2024-2034).
• The introduction of promising therapies such as MK-7264 (gefapixant), Camlipixant (BLU-5937), Orvepitant Maleate, and others is projected to drive market growth in the coming years, supported by a rise in the diagnosed prevalence of CRC.
• In 2023, the 12-month prevalence of CC in the 7MM was estimated at approximately 30 million cases. This number is anticipated to grow significantly by 2034, driven by a notable CAGR.
• In the 7MM, the United States represented nearly 42% of the 12-month prevalent cases of CC, with more than 12 million cases in 2023, a figure expected to grow by 2034.
• DelveInsight's analysts estimated that in 2023, the total diagnosed prevalent cases of CRC across the 7MM exceeded 12 million. Among these, the United States had the highest number of diagnosed prevalent cases, followed by Japan. The prevalence of CRC was determined based on the patient pool of CC.
• In 2023, the gender distribution of CC cases in the US consisted of roughly 40% males and 60% females, with forecasts suggesting an increase by 2034.
• In 2023, Germany had the highest number of diagnosed prevalent CRC cases among European countries, with 1.3 million cases, followed by the UK with 1 million cases. In contrast, Spain had the lowest number of diagnosed CRC cases among the EU4 and the UK.
• The leading Chronic Refractory Cough Companies such as Merck & Co, GSK, NeRRe Therapeutics, Trevi Therapeutics, Beijing Tide Pharmaceutical, Bellus Health Inc., Axalbion, Jiangsu Hansoh Pharma, Melius Pharma AB, Genentech, Inc., and others
• Promising Chronic Refractory Cough Therapies such as MK-7264 (gefapixant), Camlipixant, Orvepitant Maleate, AX-8, Nalbuphine ER, TCR1672 tablet, BLU-5937, HS-10383, ME-015 (Suplatast Tosilate), GDC-6599, and others

Stay ahead in the Chronic Refractory Cough Therapeutics Market with DelveInsight's Strategic Report @ Chronic Refractory Cough Market Outlook- https://www.delveinsight.com/sample-request/chronic-refractory-cough-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Refractory Cough Epidemiology Segmentation:
• Total Prevalence of Chronic Refractory Cough
• Prevalent Cases of Chronic Refractory Cough by severity
• Gender-specific Prevalence of Chronic Refractory Cough
• Diagnosed Cases of Episodic and Chronic Refractory Cough

Download the report to understand which factors are driving Chronic Refractory Cough epidemiology trends @ Chronic Refractory Cough Prevalence- https://www.delveinsight.com/sample-request/chronic-refractory-cough-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Refractory Cough Emerging Therapies
• Gefapixant (MK-7264): Merck & Co/ Kyorin Pharmaceuticals
MK-7264 (gefapixant), being developed by Merck is a selective, non-narcotic, orally administered P2X3 antagonist designed to target the mechanism by which certain nerve fibers become hypersensitized and can lead to chronic and debilitating symptoms, such as CC. It is a selective P2X3 receptor antagonist that prevents ATP binding, which has a significant role in the activation of the sensory fibers central to cough initiation. Thus MK‐7264 exerts its antagonism via negative allosteric modulation. In January 2022, the Japan MHLW approved LYFNUA (gefapixant) for the treatment of adults with RCC or UCC. However, the US FDA has issued a CRL regarding Merck's NDA for MK-7264 and requested additional information related to the measurement of efficacy.

• Camlipixant (BLU-5937): Bellus Health- a GSK company
Camlipixant (formerly known as BLU-5937), being developed by Bellus Health- a GSK company, is a potent, highly selective, oral antagonist of the P2X3 receptor, a clinically validated target for CC. BLU-5937 has the potential to be a best-in-class therapeutic for CRC patients, as it has shown to be highly selective (>1500-fold) for human P2X3 receptors versus P2X2/3 receptors. Bellus Health has completed Phase IIb (SOOTHE) trials and is currently being investigated in Phase III trials.

Chronic Refractory Cough Market Outlook
The Chronic Refractory Cough market currently faces a significant challenge with the absence of approved therapies, leaving patients with a critical unmet need. Non-pharmacologic interventions, particularly Speech Therapy and Physiotherapy, represent the cornerstone of current treatment strategies. After nonpharmacological therapies, the market holds various types of pharmacologic therapies which include neuromodulators, proton pump inhibitors, ICS, and other treatment options. Neuromodulators include opiates (morphine, codeine etc.), gabapentin, pregabalin, morphine, amitriptyline, and baclofen, which act on the heightened neural sensitization that is involved in the pathogenesis of CRC.

Chronic Refractory Cough Therapies and Companies
• MK-7264 (gefapixant): Merck & Co
• Camlipixant: GSK
• Orvepitant Maleate: NeRRe Therapeutics
• AX-8: Axalbion
• Nalbuphine ER: Trevi Therapeutics
• TCR1672 tablet: Beijing Tide Pharmaceutical
• BLU-5937: Bellus Health Inc.
• HS-10383: Jiangsu Hansoh Pharma
• ME-015 (Suplatast Tosilate): Melius Pharma AB
• GDC-6599: Genentech, Inc.

Discover more about therapies set to grab major Chronic Refractory Cough market share @ Chronic Refractory Cough Treatment Market- https://www.delveinsight.com/sample-request/chronic-refractory-cough-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Refractory Cough Market Strengths
• Growing research and development in the area may increase the probability of development of potential effective therapy for CRC.
• There is a significant increase in the prevalent population of CRC which will drive the market in the long run.

Chronic Refractory Cough Market Opportunities
• There is a lack of efficacious medication or therapy which provides an extensive market opportunity for the emerging companies to accelerate and dominate the CRC market.
• Increased public awareness creates a lucrative opportunity for innovation of therapeutics to drive CRC market.

Get In-Depth Knowledge on Chronic Refractory Cough Market Trends and Forecasts with DelveInsight @ Chronic Refractory Cough Treatment Market @ https://www.delveinsight.com/sample-request/chronic-refractory-cough-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Refractory Cough Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Chronic Refractory Cough Companies: Merck & Co, GSK, NeRRe Therapeutics, Trevi Therapeutics, Beijing Tide Pharmaceutical, Bellus Health Inc., Axalbion, Jiangsu Hansoh Pharma, Melius Pharma AB, Genentech, Inc., and others
• Chronic Refractory Cough Therapies: MK-7264 (gefapixant), Camlipixant, Orvepitant Maleate, AX-8, Nalbuphine ER, TCR1672 tablet, BLU-5937, HS-10383, ME-015 (Suplatast Tosilate), GDC-6599, and others
• Chronic Refractory Cough Therapeutic Assessment: Chronic Refractory Cough current marketed and Chronic Refractory Cough emerging therapies
• Chronic Refractory Cough Market Dynamics: Chronic Refractory Cough market drivers and Chronic Refractory Cough market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Refractory Cough Unmet Needs, KOL's views, Analyst's views, Chronic Refractory Cough Market Access and Reimbursement

To know more about Chronic Refractory Cough companies working in the treatment market, visit @ Chronic Refractory Cough Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/chronic-refractory-cough-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Chronic Refractory Cough Market Report Introduction
2. Executive Summary for Chronic Refractory Cough
3. SWOT analysis of Chronic Refractory Cough
4. Chronic Refractory Cough Patient Share (%) Overview at a Glance
5. Chronic Refractory Cough Market Overview at a Glance
6. Chronic Refractory Cough Disease Background and Overview
7. Chronic Refractory Cough Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Refractory Cough
9. Chronic Refractory Cough Current Treatment and Medical Practices
10. Chronic Refractory Cough Unmet Needs
11. Chronic Refractory Cough Emerging Therapies
12. Chronic Refractory Cough Market Outlook
13. Country-Wise Chronic Refractory Cough Market Analysis (2020-2034)
14. Chronic Refractory Cough Market Access and Reimbursement of Therapies
15. Chronic Refractory Cough Market Drivers
16. Chronic Refractory Cough Market Barriers
17. Chronic Refractory Cough Appendix
18. Chronic Refractory Cough Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Vascular access devices market- https://www.delveinsight.com/report-store/vascular-access-device-market
NK cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Ventral hernia market- ttps://www.delveinsight.com/report-store/hernia-repair-devices-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market
Total knee arthroplasty market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Baricose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Pouchitis market- https://www.delveinsight.com/report-store/pouchitis-market
Diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Transcatheter treatment market- https://www.delveinsight.com/report-store/transcatheter-treatment-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Chronic neuropathic pain market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.